TrialResults-center.org

Menu

Bococizumab PCSK9 Inhibitors

bococizumab

Cardiovascular prevention

All type of patients: 7 trials - SPIRE-1 - SPIRE-2 - SPIRE-SI - SPIRE-HR - SPIRE-LDL - SPIRE-FH - SPIRE-LL

bococizumab vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death from all causes as adverse event	no data
serious adverse events	no data
cardiovascular events as adverse event	no data
neurological SAE	no data
Neurocognitive disorder	no data
Muscle-related adverse events	no data
cardiovascular death as adverse event	no data
myocardial infarction as adverse event	no data
unstable angina as adverse death	no data
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death	no data
Allergic reactions	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -